Spin-off may signal new era for Big Pharma R&D

The Wall Street Journal notes the "dis-integration" of the traditional Big Pharma model following yesterday's announcement that AstraZeneca is spinning off its Swedish R&D facility for gastrointestinal therapies. The shop, which developed Nexium, is being spun off into Albireo Pharma, with AstraZeneca as a minority shareholder. David Chiswell, the former CEO of Cambridge Antibody Technology--bought by AstraZeneca and integrated with MedImmune--has been tapped to run the new company. Chiswell says that Albireo has several pre-clinical compounds in the hopper along with a clinical stage program he declined to name. With typical hyperbole, the Journal's health bloggers says the day may come when AstraZeneca may restrict itself to late-stage trials and drug marketing.

- see the release on Albrieo's creation
- check out the report from the Wall Street Journal

ALSO: Albireo will start off with an A round expected to top out at $40 million. Report

Related Articles:
AstraZeneca may shake up R&D with spin-off. Report
AstraZeneca drops the axe in global R&D shakeup. Report
AZ touts biologics pipeline. Report

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.